FinnCap reiterated their buy rating on shares of Shield Therapeutics PLC (LON:STX) in a research report released on Thursday morning. FinnCap currently has a GBX 270 ($3.49) price objective on the stock.
STX has been the subject of a number of other reports. Liberum Capital reaffirmed a buy rating and issued a GBX 245 ($3.16) target price on shares of Shield Therapeutics PLC in a report on Thursday, June 22nd. Peel Hunt reissued a buy rating and set a GBX 220 ($2.84) price target on shares of Shield Therapeutics PLC in a report on Thursday, July 6th.
Shield Therapeutics PLC (LON:STX) remained flat at GBX 157.50 during trading on Thursday. 2,500 shares of the stock traded hands. Shield Therapeutics PLC has a 1-year low of GBX 152.25 and a 1-year high of GBX 177.00. The firm’s 50 day moving average is GBX 157.50 and its 200-day moving average is GBX 163.10. The firm’s market cap is GBX 170.10 million.
ILLEGAL ACTIVITY NOTICE: “Shield Therapeutics PLC (STX) Given “Buy” Rating at FinnCap” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/09/15/shield-therapeutics-plc-stx-given-buy-rating-at-finncap.html.
Shield Therapeutics PLC Company Profile
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.
Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.